Seagen. has filed a patent for multi-drug Antibody Drug Conjugates (MD-ADCs) and Linking Assembly (LA) Units constructed in a site-specific manner using “orthogonal” deprotection and drug loading. The Protected Linking Assembly Units enable the construction of MD-ADCs and LA Units. GlobalData’s report on Seagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Seagen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Seagen, Nanoparticle drug conjugates was a key innovation area identified from patents. Seagen's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Multi-drug antibody drug conjugates with site-specific construction

Source: United States Patent and Trademark Office (USPTO). Credit: Seagen Inc

The filed patent (Publication Number: US20240033372A1) describes a Drug Linking Assembly Unit with specific formulas and components. The assembly unit includes various elements such as succinimido groups, amino acids, and maleimido groups, among others, to create a drug delivery system. The patent outlines the use of specific anticancer agents like MMAE and MMAF or camptothecin and doxorubicin, which have complementary activity profiles. Additionally, the assembly unit incorporates Partitioning Agents like polyethylene glycol units or cyclodextrin units to enhance drug delivery efficiency.

The Drug Linking Assembly Unit detailed in the patent offers a novel approach to drug delivery systems, particularly in the context of anticancer agents. By utilizing specific components and formulas, the assembly unit aims to improve the targeted delivery of drugs to enhance therapeutic outcomes. The inclusion of self-stabilizing linkers and specific anticancer agents with complementary profiles showcases the innovative nature of the drug delivery system. Overall, the patent provides a detailed description of the components, configurations, and potential applications of the Drug Linking Assembly Unit, highlighting its potential impact on the field of drug delivery and cancer treatment.

To know more about GlobalData’s detailed insights on Seagen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies